Yan-Ming Chen

Dr. Yan-Ming Chen


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
YCYan-Ming Chen
Yan-Ming Chen
FHFung-Rong Hu
Fung-Rong Hu
JHJehn-Yu Huang
Jehn-Yu Huang
ESElizabeth P. Shen
Elizabeth P. Shen
TTTzu-Yun Tsai
Tzu-Yun Tsai
WCWei-Li Chen
Wei-Li Chen

1 December 2010 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
CLChung-Tien Lin
Chung-Tien Lin
FHFung-Rong Hu
Fung-Rong Hu
KKKuang-Tzu Kuo
Kuang-Tzu Kuo
YCYan-Ming Chen
Yan-Ming Chen
HCHsiao-Sang Chu
Hsiao-Sang Chu
WCWei-Li Chen
Wei-Li Chen
Purpose. To compare the effects of early, mid, and late subconjunctival injection of bevacizumab on corneal neovascularization (NV) and conjunctivalization in a rabbit limbal insufficiency model. Methods. Limbal insufficiency was created surgically, and subconjunctival injections of 2.5 mg bevacizumab twice weekly for 1 month were started immediately (early group), 1 week (mid group), and 1 month after injury (late group). The corneal epithelial alterations, stromal opacity, centricity, extent, and PICS (percentage of involved corneal surface) of the corneal NV were evaluated. The expression of cytokeratins K3, K4, K12, K13, and MUC5 by the corneal surface cells was examined by immunohistochemistry. Results. Bevacizumab significantly inhibited corneal NV in the early and mid, but not the late, treatment groups at 4 weeks after treatment (PICS: P < 0.01 in the early group, P < 0.01 in the mid group, and P > 0.05 in the late group). Early and mid treatment produced significant inhibition of corneal alteration (P < 0.01 in the early group and P = 0.03 in the mid group) and stromal opacity (P < 0.01 in the early group and P = 0.02 in the mid group) at 4 months after treatment but not in the late group. The immunohistochemistry of cytokeratin on the corneal surface cells at 1 month after treatment was K3(+), K4(−), K12(+), K13(−), and MUC5(−) in the early group; K3(+), K4(+), K12(+), K13(+), and MUC5(−) in the mid group; and K3(+), K4(+), K12(−), K13(+), and MUC5(+) in the late treatment group. Conclusions. Early and mid bevacizumab injection inhibited corneal NV, epithelial alteration, and stromal opacity in limbal insufficiency, but late treatment did not. Early treatment with bevacizumab seems to be clinically beneficial in the management of limbal injury such as chemical burn.

8 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WCWei-Li Chen
Wei-Li Chen
YCYan-Ming Chen
Yan-Ming Chen
HCHsiao-Sang Chu
Hsiao-Sang Chu
CLChung-Tien Lin
Chung-Tien Lin
LCLuping Chow
Luping Chow
FHFung-Rong Hu
Fung-Rong Hu
To evaluate the effects and underlying mechanisms of early and late subconjunctival injection of bevacizumab on the inhibition of corneal neovascularization (NV). Corneal NV was induced by closed eye contact lens wear followed by a silk suture tarsorrhaphy in rabbits. Weekly subconjunctival injections of bevacizumab (5.0 mg) for 1 month were started immediately (early treatment group) or 1 month after induction of corneal NV with continuous induction (late treatment group). The severity of corneal NV was evaluated. Immunostaining was used to evaluate the intracorneal diffusion of bevacizumab, and the existence of pericytes and smooth muscle cells around the NV. The expression of AM-3K, an anti-macrophage antibody, vascular endothelial growth factor (VEGF) with its receptors (VEGFR1 and VEGFR2), and vascular endothelial apoptosis were also evaluated. Western blot analysis was performed to quantify the expression level of VEGF, VEGFR1 and VEGFR2 on corneal epithelium and stroma in different groups. Early treatment with bevacizumab inhibited corneal NV more significantly than late treatment. Intracorneal diffusion of bevacizumab was not different among different groups. Immunostaining showed pericytes and smooth muscle cells around newly formed vessels as early as 2 weeks after induction. Immunostaining and Western blot analysis showed that VEGF, VEGFR1, and VEGFR2 on corneal stroma increased significantly in no treatment groups and late treatment groups, but not in early treatment group. Bevacizumab significantly inhibited macrophage infiltration in the early but not late treatment group. Sporadic vascular endothelial apoptosis was found at 4 weeks in the late but not early treatment group. Early but not late injection of bevacizumab inhibited corneal NV. Late injection of bevacizumab did not alter macrophage infiltration, and can't inhibit the expression of VEGF, VEGFR1, and VEGFR2 on corneal vessels. The inhibition of corneal NV in early treatment group does not occur via vascular endothelial apoptosis.

1 January 2011 in Cornea
Verified
Journal Article
Closed access
HCHsiao-Sang Chu
Hsiao-Sang Chu
FHFung-Rong Hu
Fung-Rong Hu
CYChung-May Yang
Chung-May Yang
PYPo-Ting Yeh
Po-Ting Yeh
YCYan-Ming Chen
Yan-Ming Chen
WCWei-Li Chen
Wei-Li Chen
To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy. A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests. After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects. The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.

1 January 2006 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
PSPei-Yuang Su
Pei-Yuang Su
FHFung-Rong Hu
Fung-Rong Hu
YCYan-Ming Chen
Yan-Ming Chen
JHJen-Hui Han
Jen-Hui Han
WCWei-Li Chen
Wei-Li Chen
Purpose: To report the in-vivo confocal microscopic findings of dendritiform cells in the central corneal epithelial layer in a case of mixed bacterial keratitis associated with severe immunologic reaction. Design: Observational case report. Methods: A 25-year-old male suffered from contact lens-related mixed bacterial keratitis with a dense eccentric immune ring. In-vivo confocal microscopy was performed to study the different layers of the central and peripheral cornea in the lesion and the fellow eye. Results: Several dendritiform cells were found in the basal and superficial epithelial layers of the central cornea in the lesion eye, which was also the area of the dense immune ring formation. No such cells could be identified in the fellow eye or the unaffected area of the lesion eye. Conclusion: Corneal dendritiform cells, possibly dendritic or Langerhans cells, can be identified in severe corneal immunologic conditions using in-vivo confocal microscopy. The role of these cells in ocular immunity is interesting and needs further clarification.

1 December 2016 in Contact Lens and Anterior Eye
Verified
Journal Article
Closed access
YLYu Kuei Lee
Yu Kuei Lee
YLYen-Chun Lin
Yen-Chun Lin
STShih-Hao Tsai
Shih-Hao Tsai
WCWei-Li Chen
Wei-Li Chen
YCYan-Ming Chen
Yan-Ming Chen